Insider Transactions in Q1 2024 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$160,000
$16.01 P/Share
|
|
Mar 11
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
30,000
-2.45%
|
$450,000
$15.24 P/Share
|
|
Feb 27
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
20,000
-1.61%
|
$320,000
$16.11 P/Share
|
|
Feb 16
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,242
-16.35%
|
$48,630
$15.25 P/Share
|
|
Feb 16
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,666
-0.95%
|
$39,990
$15.25 P/Share
|
|
Feb 16
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
2,258
-0.18%
|
$33,870
$15.25 P/Share
|
|
Feb 16
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,615
-1.04%
|
$114,225
$15.25 P/Share
|
|
Feb 15
2024
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
8,399
+14.18%
|
-
|
|
Feb 15
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
10,250
+1.21%
|
-
|
|
Feb 15
2024
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,686
+0.23%
|
-
|
|
Feb 15
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,999
+0.91%
|
-
|